• Most Popular
  • Most Shared

Crucell to cancel West Nile vaccine programme

Tue Feb 12, 2008 2:17am EST

Stocks

   

AMSTERDAM, Feb 12 (Reuters) - Dutch biotechnology firm Crucell (CRCL.AS) (CRXL.O) said on Tuesday it would discontinue its programme to develop a vaccine and human monoclonal antibodies for therapeutic use against West Nile.

"Crucell has come to the conclusion that the commercial and market opportunities for its West Nile products are not as attractive as other products in Crucell's pipeline," the company said in a statement.

Crucell also said to further postpone the registration submission of the Yellow Fever vaccine, called Flavimum, in Switzerland.

Crucell said it would focus on its MoRuViraten vaccine for Measles/Rubella, which is produced in the same facility as Flavimun. (Reporting by Harro ten Wolde)



More from Reuters

Photo

Home prices flat after five months of gains

NEW YORK (Reuters) - U.S. home prices were unchanged in October, according to the widely watched Standard & Poor's/Case-Shiller indexes released on Tuesday, indicating stabilization in the hard-hit housing sector though the figures dashed hopes for a sixth straight monthly increase.

» More Top News
An employee swipes a customer's credit card through the card reader at a restaurant in Tokyo February 19, 2005.REUTERS/Issei Kato

Taking a swipe at credit cards

New legislation meant to protect consumers could be a "game changer" for the industry -- and not in a good way.  Full Article 

Economy
dealer shuffles a deck of cards during a poker game at a casino in Budapest September 15, 2009. REUTERS/Katoly Arvai

Placing their bets

Two IPO filings will test investors' appetite for risk that they probably would've avoided in the past year.  Full Article 

DEALS